Literature DB >> 1702723

Selective lysis of the autologous tumor by delta TCS1+ gamma/delta+ tumor-infiltrating lymphocytes from human lung carcinomas.

M R Zocchi1, M Ferrarini, C Rugarli.   

Abstract

Two distinct non-overlapping populations of TcR1+ (gamma/delta) T cells have been described: the first, bearing the disulfide-linked gamma/delta heterodimer, is predominant in the peripheral blood; the second, expressing the non-disulfide-linked form of TcR1, is mostly confined to epithelial tissues (lung, gut, skin). TcR1+ lymphocytes may be cytotoxic and could be involved in anti-tumor immunity, especially against tumors at epithelial sites. Freshly derived tumor-infiltrating lymphocytes (TIL) obtained from two patients with lung cancer were enriched in CD3+WT31- cells. The percentage of this subset substantially increased upon culture in the presence of interleukin 2. These cells were TcR1+ as demonstrated by immunofluorescence and immunoprecipitation. In one case only 40% of this population reacted with delta TCS1 mAb, that recognizes the non-disulfide-linked form of TcR1, and co-expressed the CD8 antigen. Cultured TcR1+ TIL were able to kill fresh autologous tumor cells, K-562 and, to a lesser extent, some natural killer-resistant cell lines and allogeneic lung tumor cells in 4-h 51Cr-release cytotoxicity assays. The fractionated delta TCS1+ TIL lysed only autologous tumor cells and K-562, whereas the lytic activity against all the other targets was confined to the delta TCS1- subset. Moreover, the autotumor cytotoxicity was inhibited by anti-HLA class I but not by anti-CD1c or anti-LFA-1 mAb, suggesting that killing of the autologous tumor cells and non-major histocompatibility complex-restricted cytotoxicity are mediated by different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1702723     DOI: 10.1002/eji.1830201224

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  28 in total

1.  {gamma}{delta} T cell homeostasis is established in competition with {alpha}{beta} T cells and NK cells.

Authors:  Jena D French; Christina L Roark; Willi K Born; Rebecca L O'brien
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

Review 2.  Role of gamma-delta T-cells in cancer: another opening door to immunotherapy.

Authors:  Diego Marquez-Medina; Joel Salla-Fortuny; Antonieta Salud-Salvia
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

3.  Characterization of γδ T cells in patients with non-small cell lung cancer.

Authors:  Yi Bao; Li Guo; Juanfen Mo
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

4.  Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB.

Authors:  V Groh; R Rhinehart; H Secrist; S Bauer; K H Grabstein; T Spies
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 5.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

Review 6.  Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.

Authors:  Stephanie Strobl; Kerstin Wimmer; Ruth Exner; Yelena Devyatko; Michael Bolliger; Florian Fitzal; Michael Gnant
Journal:  Curr Treat Options Oncol       Date:  2018-03-12

Review 7.  Eicosanoids and the immunology of cancer.

Authors:  M R Young
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

8.  T-cell receptor V delta gene usage by tumour reactive gamma delta T lymphocytes infiltrating human lung cancer.

Authors:  M R Zocchi; M Ferrarini; N Migone; G Casorati
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

Review 9.  Immunoregulatory cells for transplantation tolerance and graft-versus-leukemia effect.

Authors:  Masahiro Imamura; Junji Tanaka
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

Review 10.  Cytotoxic and regulatory properties of circulating Vδ1+ γδ T cells: a new player on the cell therapy field?

Authors:  Gabrielle M Siegers; Lawrence S Lamb
Journal:  Mol Ther       Date:  2014-06-04       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.